Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 17/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 16/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661108 | 0.84 | ADORA2B (1.00) | ADORA2BADORA1ADORA2AADORA3KDM4E | |
| SCHEMBL1945925 | 0.83 | ADORA2A (1.00) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL2533013 | 0.82 | ADORA2B (0.70) | ADORA2BADORA1ADORA2AADORA3KDM4E | |
| SCHEMBL1946606 | 0.82 | ADORA2B (1.00) | ADORA2BADORA1ADORA2AADORA3KDM4E | |
| SCHEMBL1946601 | 0.81 | ADORA2A (1.00) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL12245131 | 0.81 | ADORA2B (1.00) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL4763899 | 0.81 | ADORA2A (0.67) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL238937 | 0.80 | ADORA2B (0.67) | ADORA2BADORA1ADORA2AADORA3KDM4E | |
| SCHEMBL1945555 | 0.80 | ADORA2B (0.75) | ADORA2BADORA1ADORA2AADORA3KDM4E | |
| SCHEMBL1947598 | 0.80 | ADORA2B (0.74) | ADORA2BADORA1ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20080318983-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20080318983-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.